Results 101 to 110 of about 4,828 (174)

Modeling the greenhouse gas emissions of an immunization program against respiratory syncytial virus in infants in the United Kingdom. [PDF]

open access: yesInt J Technol Assess Health Care
Hudson RDA   +4 more
europepmc   +1 more source

Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. [PDF]

open access: yesHum Vaccin Immunother
Paes BA   +4 more
europepmc   +1 more source

Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. [PDF]

open access: yesFront Pediatr
Tonetto S   +10 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants. [PDF]

open access: yesClin Drug Investig
Bini C   +10 more
europepmc   +1 more source

New Drugs: Palivizumab

open access: yesAustralian Prescriber, 1999
openaire   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study. [PDF]

open access: yesBMJ Public Health
Gil-Prieto R   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy